The Clinical and Forensic Toxicology of Z-drugs

Journal of Medical Toxicology

Volumn 9, Issue 2, 2013, Pages 155-162

  Gunja, Naren ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Analysis; Poisoning; Zaleplon; Zolpidem; Zopiclone

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTIFUNGAL AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; CHLORPROMAZINE; CIMETIDINE; CIPROFLOXACIN; ERYTHROMYCIN; ESZOPICLONE; FLUMAZENIL; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; PROTEINASE INHIBITOR; RIFAMPICIN; THIORIDAZINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AMNESIA; ARTICLE; BITTER TASTE; COMA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MECHANISM; DRUG OVERDOSE; DRUG URINE LEVEL; FORENSIC TOXICOLOGY; GABAERGIC TRANSMISSION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PARASOMNIA; PRURITUS; PSYCHOMOTOR PERFORMANCE; PSYCHOSIS; SIDE EFFECT; SLEEP; SLEEP QUALITY; SLEEP TIME; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER; XEROSTOMIA;

ACETAMIDES; AZABICYCLO COMPOUNDS; COMA; DRUG OVERDOSE; FLUMAZENIL; GABA MODULATORS; GABA-A RECEPTOR AGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; PIPERAZINES; PYRIDINES; PYRIMIDINES;

EID: 84878109850     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-013-0292-0     Document Type: Article

References (82)

1. Montplaisir J, Hawa R, Moller H et al (2003) Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 18(1): 29-38.
2. Stewart R, Besset A, Bebbington P et al (2006) Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 29(11): 1391-1397.
3. Glass J, Lanctot KL, Herrmann N et al (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331(7526): 1169.
4. Dolder C, Nelson M, McKinsey J (2007) Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 21(5): 389-405.
5. Dang A, Garg A, Rataboli PV (2011) Role of zolpidem in the management of insomnia. CNS Neurosci Ther 17(5): 387-397.
6. Wagner J, Wagner ML (2000) Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 4(6): 551-581.
7. Dolder CR, Nelson MH (2008) Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 22(12): 1021-1036.
8. Barbera J, Shapiro C (2005) Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 28(4): 301-318.
9. Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep medication on driving ability. Sleep Med Rev 8(4): 309-325.
10. A receptor modulators as hypnotics. J Psychopharmacol 24(11): 1601-1612.
11. Sanofi-Aventis (2012) Product Information: Stilnox ® CR Modified Release Tablets. http://products. sanofi. com. au/aus_pi_stilnoxCR. pdf Accessed on 1 Dec 2012.
12. Barkin RL (2007) Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 14(3): 299-305.
13. Holm KJ, Goa KL (2000) Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59(4): 865-889.
14. Nutt DJ, Feetam CL (2010) What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. J Psychopharmacol 24(8): 1137-1141.
15. George CF (2001) Pyrazolopyrimidines. Lancet 358(9293): 1623-1626.
16. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43(4): 227-238.
17. Greenblatt DJ, Legangneux E, Harmatz JS et al (2006) Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 46(12): 1469-1480.
18. Halas CJ (2006) Eszopiclone. Am J Health Syst Pharm 63(1): 41-48.
19. Najib J (2006) Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 28(4): 491-516.
20. Staner L, Eriksson M, Cornette F et al (2009) Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med 10(6): 616-620.
21. US Food & Drug Administration (2013) FDA requires lower recommended doses for certain drugs containing zolpidem http://www. fda. gov/Drugs/DrugSafety/ucm334033. htm Accessed 20 Jan 2013.
22. Brunello N, Bettica P, Amato D et al (2008) Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone. Eur Neuropsychopharmacol 18(S4): S581-S582.
23. Fernandez C, Maradeix V, Gimenez F et al (1993) Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 21(6): 1125-1128.
24. Cienki JJ, Burkhart KK, Donovan JW (2005) Zopiclone overdose responsive to flumazenil. Clin Toxicol (Phila) 43(5): 385-386.
25. Yang C-C, Deng J-F (2008) Utility of flumazenil in zopiclone overdose. Clin Toxicol (Phila) 46(9): 920-921.
26. Patat A, Naef MM, van Gessel E et al (1994) Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 56(4): 430-436.
27. Hojer J, Salmonson H, Sundin P (2002) Zaleplon-induced coma and bluish-green urine: possible antidotal effect by flumazenil. J Toxicol Clin Toxicol 40(5): 571-572.
28. Olubodun JO, Ochs HR, Truten V et al (2002) Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol 42(10): 1142-1146.
29. Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9(6): 364-377.
30. Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 17(7): 513-532.
31. Hojo Y, Echizenya M, Ohkubo T et al (2011) Drug interaction between St John's wort and zolpidem in healthy subjects. J Clin Pharm Ther 36(6): 711-715.
32. Swainston Harrison T, Keating GM (2005) Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19(1): 65-89.
33. Vlase L, Popa A, Neag M et al (2011) Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. J Clin Pharmacol 51(8): 1233-1236.
34. Vlase L, Popa A, Neag M et al (2011) Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet 35(3-4): 83-87.
35. US Food & Drug Administration (2007) FDA Requests Label Change for All Sleep Disorder Drug Products. http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108868. htm Accessed 1 Dec 2012.
36. Duggal HS (2007) New-onset transient hallucinations possibly due to eszopiclone: a case study. Prim Care Companion J Clin Psychiatry 9(6): 468-469.
37. Stone JR, Zorick TS, Tsuang J (2008) Dose-related illusions and hallucinations with zaleplon. Clin Toxicol (Phila) 46(4): 344-345.
38. Tsai MJ, Huang YB, Wu PC (2003) A novel clinical pattern of visual hallucination after zolpidem use. J Toxicol Clin Toxicol 41(6): 869-872.
39. Elko CJ, Burgess JL, Robertson WO (1998) Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 36(3): 195-203.
40. Sanger DJ (2004) The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18(S1): 9-15.
41. Hajak G, Muller WE, Wittchen HU et al (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98(10): 1371-1378.
42. Chien C-C, Huanga H-T, Lung F-W et al (2011) Zolpidem withdrawal delirium, seizure, and acute psychosis: case reports and literature review. J Subs Use 16(4): 330-338.
43. Greenblatt DJ, Roth T (2012) Zolpidem for insomnia. Expert Opin Pharmacother 13(6): 879-893.
44. Victorri-Vigneau C, Dailly E, Veyrac G et al (2007) Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 64(2): 198-209.
45. Cimolai N (2007) Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 53(12): 2124-2129.
46. Tonon MA, Bonato PS (2012) Methods for the analysis of nonbenzodiazepine hypnotic drugs in biological matrices. Bioanalysis 4(3): 291-304.
47. Boniface PJ, Russell SG (1996) Two cases of fatal zopiclone overdose. J Anal Toxicol 20(2): 131-133.
48. Han E, Kim E, Hong H et al (2012) Evaluation of postmortem redistribution phenomena for commonly encountered drugs. Forensic Sci Int 219(1-3): 265-271.
49. Kintz P, Villain M, Concheiro M et al (2005) Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS. Forensic Sci Int 150(2-3): 213-220.
50. Leikin JB, Watson WA (2003) Post-mortem toxicology: what the dead can and cannot tell us. J Toxicol Clin Toxicol 41(1): 47-56.
51. Levine B (2010) Principles of forensic toxicology. AACC, Washington, DC.
52. Rust KY, Baumgartner MR, Meggiolaro N et al (2012) Detection and validated quantification of 21 benzodiazepines and 3 "z-drugs" in human hair by LC-MS/MS. Forensic Sci Int 215(1-3): 64-72.
53. Drover D, Lemmens H, Naidu S et al (2000) Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 22(12): 1443-1461.
54. Scott-Ham M, Burton FC (2005) Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 12(4): 175-186.
55. Bramness JG, Arnestad M, Karinen R et al (2001) Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma. J Forensic Sci 46(5): 1247-1249.
56. Garnier R, Guerault E, Muzard D et al (1994) Acute zolpidem poisoning-analysis of 344 cases. J Toxicol Clin Toxicol 32(4): 391-404.
57. Gjerde H, Christophersen AS, Normann PT et al (2011) Toxicological investigations of drivers killed in road traffic accidents in Norway during 2006-2008. Forensic Sci Int 212(1-3): 102-109.
58. Gock SB, Wong SH, Nuwayhid N et al (1999) Acute zolpidem overdose-report of two cases. J Anal Toxicol 23(6): 559-562.
59. Jones AW, Holmgren A (2012) Concentrations of zolpidem and zopiclone in venous blood samples from impaired drivers compared with femoral blood from forensic autopsies. Forensic Sci Int 222(1-3): 118-123.
60. Sanofi-Aventis (2011) Product monograph: Imovane (zopiclone). http://products. sanofi. ca/en/imovane. pdf Accessed 1 Dec 2012.
61. Takayasu T, Ishida Y, Kimura A et al (2008) Distribution of zolpidem in body fluids and organ tissues in five autopsy cases. Forensic Toxicol 26(2): 80-84.
62. Baselt RC (2004) Disposition of toxic drugs and chemicals in man. Biomedical, Foster.
63. Bosker WM, Huestis MA (2009) Oral fluid testing for drugs of abuse. Clin Chem 55(11): 1910-1931.
64. Laloup M, Ramirez Fernandez Mdel M, De Boeck G et al (2005) Validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of 26 benzodiazepines and metabolites, zolpidem and zopiclone, in blood, urine, and hair. J Anal Toxicol 29(7): 616-626.
65. Kintz P (2012) Value of the concept of minimal detectable dosage in human hair. Forensic Sci Int 218(1-3): 28-30.
66. Anderson DT, Budd RD (2009) Zaleplon (Sonata) analysis in postmortem specimens by gas chromatography-electron capture detection. J Anal Toxicol 33(8): 481-485.
67. Levine B, Wu SC, Smialek JE (1999) Zolpidem distribution in postmortem cases. J Forensic Sci 44(2): 369-371.
68. Pounder DJ, Davies JI (1994) Zopiclone poisoning: tissue distribution and potential for postmortem diffusion. Forensic Sci Int 65(3): 177-183.
69. Zosel A, Osterberg EC, Mycyk MB (2011) Zolpidem misuse with other medications or alcohol frequently results in intensive care unit admission. Am J Ther 18(4): 305-308.
70. Louis CJ, Fernandez B, Beaumont C et al (2008) A case of zaleplon overdose. Clin Toxicol (Phila) 46(8): 782.
71. Kuzniar TJ, Balagani R, Radigan KA et al (2010) Coma with absent brainstem reflexes resulting from zolpidem overdose. Am J Ther 17(5): e172-e174.
72. Hamad A, Sharma N (2001) Acute zolpidem overdose leading to coma and respiratory failure. Intensive Care Med 27(7): 1239.
73. Lovett B, Watts D, Grossman M (2007) Prolonged coma after eszopiclone overdose. Am J Emerg Med 25(6): 735, e735-736.
74. Fung HT, Lai CH, Wong OF et al (2008) Two cases of methemoglobinemia following zopiclone ingestion. Clin Toxicol (Phila) 46(2): 167-170.
75. Fung HT, Lai CH, Wong OF et al (2009) Hemolytic anemia after zopiclone overdose. Clin Toxicol (Phila) 47(9): 902-903.
76. Kung SW, Tse ML, Chan YC et al (2008) Zopiclone-associated methemoglobinemia and renal impairment. Clin Toxicol (Phila) 46(10): 1099-1100.
77. Kurta DL, Myers LB, Krenzelok EP (1997) Zolpidem (Ambien): a pediatric case series. J Toxicol Clin Toxicol 35(5): 453-457.
78. Carbajal R, Blanc P, Paupe A et al (1996) Flumazenil dans les intoxications au Zolpidem chez l'enfant. Arch Ped 3(2): 191-192.
79. Darke S, Deady M, Duflou J (2012) Toxicology and characteristics of deaths involving zolpidem in New South Wales, Australia 2001-2010. J Forensic Sci 57(5): 1259-1262.
80. Buckley NA, McManus PR (2004) Changes in fatalities due to overdose of anxiolytic and sedative drugs in the UK (1983-1999). Drug Saf 27(2): 135-141.
81. Reith DM, Fountain J, McDowell R et al (2003) Comparison of the fatal toxicity index of zopiclone with benzodiazepines. J Toxicol Clin Toxicol 41(7): 975-980.
82. Moore KA, Zemrus TL, Ramcharitar V et al (2003) Mixed drug intoxication involving zaleplon ("Sonata"). Forensic Sci Int 134(2-3): 120-122.